POTENCIAIS ALVOS MOLECULARES PARA O DESENVOLVIMENTO DE NOVOS FÁRMACOS ANTITUBERCULOSE
Main Author: | |
---|---|
Publication Date: | 2017 |
Other Authors: | , |
Format: | Article |
Language: | por |
Source: | Química Nova (Online) |
Download full: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422017000500572 |
Summary: | Tuberculosis (TB) is an infectious disease caused by mycobacteria from the Mycobacterium genus, mainly by Mycobacterium tuberculosis (MTB). The World Health Organization (WHO) aims to reduce the number of TB cases worldwide in the coming years. Nevertheless, the increasing number of multidrug-resistant (MDR-TB) and extensive-drug resistance (XDR-TB) strains, and the ineffectiveness of the current treatment in latent tuberculosis are challenges to be overcome. In this review, we will demonstrate the recent advances in the tuberculosis drug discovery, focusing the research of new molecular targets in the Mycobacterium tuberculosis. Among the promising targets described herein, we highlight those, which act in different pathways in the mycobacteria, such as energy metabolism, cell wall biosynthesis, DNA synthesis, iron metabolism and transport through membranes. Furthermore, bioactive compounds discovered using phenotypic assays screening and validated through genetic approaches are also presented. |
id |
SBQ-3_3e5049d01e52990179c556a57442f12e |
---|---|
oai_identifier_str |
oai:scielo:S0100-40422017000500572 |
network_acronym_str |
SBQ-3 |
network_name_str |
Química Nova (Online) |
repository_id_str |
|
spelling |
POTENCIAIS ALVOS MOLECULARES PARA O DESENVOLVIMENTO DE NOVOS FÁRMACOS ANTITUBERCULOSEmedicinal chemistrytuberculosisMycobacterium tuberculosismolecular targetsnew drugsTuberculosis (TB) is an infectious disease caused by mycobacteria from the Mycobacterium genus, mainly by Mycobacterium tuberculosis (MTB). The World Health Organization (WHO) aims to reduce the number of TB cases worldwide in the coming years. Nevertheless, the increasing number of multidrug-resistant (MDR-TB) and extensive-drug resistance (XDR-TB) strains, and the ineffectiveness of the current treatment in latent tuberculosis are challenges to be overcome. In this review, we will demonstrate the recent advances in the tuberculosis drug discovery, focusing the research of new molecular targets in the Mycobacterium tuberculosis. Among the promising targets described herein, we highlight those, which act in different pathways in the mycobacteria, such as energy metabolism, cell wall biosynthesis, DNA synthesis, iron metabolism and transport through membranes. Furthermore, bioactive compounds discovered using phenotypic assays screening and validated through genetic approaches are also presented.Sociedade Brasileira de Química2017-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422017000500572Química Nova v.40 n.5 2017reponame:Química Nova (Online)instname:Sociedade Brasileira de Química (SBQ)instacron:SBQ10.21577/0100-4042.20170016info:eu-repo/semantics/openAccessFernandes,Guilherme Felipe dos SantosChin,Chung ManSantos,Jean Leandro dospor2017-07-04T00:00:00Zoai:scielo:S0100-40422017000500572Revistahttps://www.scielo.br/j/qn/ONGhttps://old.scielo.br/oai/scielo-oai.phpquimicanova@sbq.org.br1678-70640100-4042opendoar:2017-07-04T00:00Química Nova (Online) - Sociedade Brasileira de Química (SBQ)false |
dc.title.none.fl_str_mv |
POTENCIAIS ALVOS MOLECULARES PARA O DESENVOLVIMENTO DE NOVOS FÁRMACOS ANTITUBERCULOSE |
title |
POTENCIAIS ALVOS MOLECULARES PARA O DESENVOLVIMENTO DE NOVOS FÁRMACOS ANTITUBERCULOSE |
spellingShingle |
POTENCIAIS ALVOS MOLECULARES PARA O DESENVOLVIMENTO DE NOVOS FÁRMACOS ANTITUBERCULOSE Fernandes,Guilherme Felipe dos Santos medicinal chemistry tuberculosis Mycobacterium tuberculosis molecular targets new drugs |
title_short |
POTENCIAIS ALVOS MOLECULARES PARA O DESENVOLVIMENTO DE NOVOS FÁRMACOS ANTITUBERCULOSE |
title_full |
POTENCIAIS ALVOS MOLECULARES PARA O DESENVOLVIMENTO DE NOVOS FÁRMACOS ANTITUBERCULOSE |
title_fullStr |
POTENCIAIS ALVOS MOLECULARES PARA O DESENVOLVIMENTO DE NOVOS FÁRMACOS ANTITUBERCULOSE |
title_full_unstemmed |
POTENCIAIS ALVOS MOLECULARES PARA O DESENVOLVIMENTO DE NOVOS FÁRMACOS ANTITUBERCULOSE |
title_sort |
POTENCIAIS ALVOS MOLECULARES PARA O DESENVOLVIMENTO DE NOVOS FÁRMACOS ANTITUBERCULOSE |
author |
Fernandes,Guilherme Felipe dos Santos |
author_facet |
Fernandes,Guilherme Felipe dos Santos Chin,Chung Man Santos,Jean Leandro dos |
author_role |
author |
author2 |
Chin,Chung Man Santos,Jean Leandro dos |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Fernandes,Guilherme Felipe dos Santos Chin,Chung Man Santos,Jean Leandro dos |
dc.subject.por.fl_str_mv |
medicinal chemistry tuberculosis Mycobacterium tuberculosis molecular targets new drugs |
topic |
medicinal chemistry tuberculosis Mycobacterium tuberculosis molecular targets new drugs |
description |
Tuberculosis (TB) is an infectious disease caused by mycobacteria from the Mycobacterium genus, mainly by Mycobacterium tuberculosis (MTB). The World Health Organization (WHO) aims to reduce the number of TB cases worldwide in the coming years. Nevertheless, the increasing number of multidrug-resistant (MDR-TB) and extensive-drug resistance (XDR-TB) strains, and the ineffectiveness of the current treatment in latent tuberculosis are challenges to be overcome. In this review, we will demonstrate the recent advances in the tuberculosis drug discovery, focusing the research of new molecular targets in the Mycobacterium tuberculosis. Among the promising targets described herein, we highlight those, which act in different pathways in the mycobacteria, such as energy metabolism, cell wall biosynthesis, DNA synthesis, iron metabolism and transport through membranes. Furthermore, bioactive compounds discovered using phenotypic assays screening and validated through genetic approaches are also presented. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-06-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422017000500572 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422017000500572 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
10.21577/0100-4042.20170016 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Química |
publisher.none.fl_str_mv |
Sociedade Brasileira de Química |
dc.source.none.fl_str_mv |
Química Nova v.40 n.5 2017 reponame:Química Nova (Online) instname:Sociedade Brasileira de Química (SBQ) instacron:SBQ |
instname_str |
Sociedade Brasileira de Química (SBQ) |
instacron_str |
SBQ |
institution |
SBQ |
reponame_str |
Química Nova (Online) |
collection |
Química Nova (Online) |
repository.name.fl_str_mv |
Química Nova (Online) - Sociedade Brasileira de Química (SBQ) |
repository.mail.fl_str_mv |
quimicanova@sbq.org.br |
_version_ |
1750318118337511424 |